Metabolic Liver Disease

Latest Articles

Patients With Nonalcoholic Fatty Liver Disease May Benefit From Daily Aspirin Use

By

Lauren Dembeck, PhD

Publish Date January 3, 2020

In this prospective study of patients with biopsy-proven NAFLD, daily aspirin use was associated with less severe histologic features of NAFLD and NASH, and with lower risk for progression to advanced fibrosis.

Diabetes Drugs Compared for NAFLD Treatment

By

Cassandra Pardini, PharmD

Publish Date December 26, 2019

Findings of the analysis also revealed that some evidence indicates that liraglutide improves liver fat, liver function, and HbA1c, and may aid in NASH resolution and weight reduction.

Priority Review Granted to Obeticholic Acid for Fibrosis Due to NASH

By

Diana Ernst, RPh

Publish Date December 5, 2019

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for obeticholic acid (Intercept) for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).

Nonalcoholic Fatty Liver Disease May Improve With Diets Low in Glycemic Index, Load

By

Laurell Haapanen

Publish Date November 27, 2019

Carbohydrate quality in diet may play a potential role in improvement of hepatic fat mass and ALT level in NAFLD.

Obesity Is the Most Common Risk Factor for Chronic Liver Disease

By

Gastroenterology Advisor Contributing Writer

Publish Date November 26, 2019

Whether single or additive, obesity is a significant risk factor for chronic liver disease.

Investigational Ubrogepant Does Not Confer Hepatotoxicity in Healthy Individuals

By

Brandon May

Publish Date November 8, 2019

Investigators aimed to evaluate the safety and tolerability of ubrogepant, focusing on hepatic safety, when administered intermittently with high-frequency dosing in healthy participants.

Tesamorelin May Aid Patients With HIV, Fatty Liver Disease

Publish Date October 23, 2019

Tesamorelin significantly reduced hepatic fat fraction compared with placebo

Lanifibranor Gets Fast Track Status for Non-Alcoholic Steatohepatitis

By

Brian Park, PharmD

Publish Date October 8, 2019

The FDA has granted Fast Track designation to lanifibranor (Inventiva) for the treatment of non-alcoholic steatohepatitis.

Examining Serum Hepatic Enzymes, Lipid Profile, and Glycemic Control in T2D

By

Tyler Rice

Publish Date October 1, 2019

Researchers found that mean hepatic enzyme levels were jointly and significantly associated with poorly controlled T2D.

Fluoride Exposure Tied to Kidney, Liver Function Changes in Youth

Publish Date September 10, 2019

This study’s findings suggest that there may be potential kidney and liver health concerns to consider when evaluating fluoride use and appropriate levels in public health interventions.

Diagnosing Fibrosis Stage in NAFLD: Transient Elastography Better Than Point Shear Wave Elastography

By

Gastroenterology Advisor Contributing Writer

Publish Date August 1, 2019

Study results showed that transient elastography was good for the diagnosis of all fibrosis stages and was superior compared with point shear wave elastography for the diagnosis of fibrosis stages ≥F2 and ≥F3.

ARO-AAT Receives Fast Track Status for Treatment of Rare Genetic Liver Disease

By

Brian Park, PharmD

Publish Date July 23, 2019

The FDA has granted Fast Track designation to ARO-AAT an investigational treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency